Sunesis To Move Novel Cell-Cycle Inhibitor Forward In Small Cell Lung Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm believes the drug, SNS-595, could offer an improved toxicity profile over GSK's Hycamtin.
You may also be interested in...
Sunesis: Top-Line Phase II Data Positive In Ovarian Cancer
Early results generate interest from would-be partners, company tells “The Pink Sheet” DAILY.
Celgene To Submit Revlimid Phase III Special Protocol Assessment For CLL To FDA Shortly
Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.